Back to Search

BMS-986525 for Relapsed/Refractory Small Cell Lung Cancer

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

Recruiting Phase 1 Phase 2 Interventional Study
Relapsed/Refractory Small Cell Lung Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
240 (estimated)
Sponsor
Bristol-Myers Squibb · Industry
Who this trial is looking for

This trial is looking for people with a specific type of lung cancer that hasn’t responded to treatment. Participants will take a medication called BMS-986525 alone or with another drug, Pumitamig.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with relapsed/refractory small cell lung cancer.
  • I have received at least one type of platinum-based chemotherapy.
  • I have either progressed on, am ineligible for, or do not have access to anti-PD-(L)1 therapy.

You may not be able to join if

  • I have untreated CNS metastases.
  • I have an active autoimmune disease.
  • I have had a prior organ or tissue transplant.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria * Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC). * Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines. * In count…
Contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286

Clinical.Trials@bms.com

CONTACT

First line of the email MUST contain NCT # and Site #.

CONTACT

NCT ID: NCT07325136 Source: ClinicalTrials.gov